One of these 2 turnaround stocks could make you rich

Harvey Jones says one of these stocks is now on the road to recovery.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Clinical-stage biopharmaceutical company PureTech Health (LSE: PRTC) is in the early stages of a promising turnaround. It shares still trade 12% lower than a year ago, despite recovering lost ground in recent months, so there could be an opportunity here.

Keep it Pure 

PureTech’s shares are up almost 3% today after it published its half-yearly report to 30 June, which showed a combination of rising revenues but bigger losses. That’s not unusual in the famously risky biopharma sector, as the group advances more than 20 late and mid-stage clinical programmes and pre-clinical products.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

Today it reported significant progress across its pipeline and said it expects to pass a number of key milestones over the next 12 months. The London-listed, Boston-based firm, which has a market cap of £322m, posted a pre-tax loss of $67.2m, up 40% on last year’s $44.5m loss. Most of this went on research and development, which is exactly how a company like this should be spending its money.

Tech boom

Revenue jumped an impressive 92% year-on-year even though its operations do not yet generate consistent product revenues, as is customary with pre-commercial biopharma companies. These revenues related primarily to passing milestones on collaborations with third parties. PureTech expects to earn future revenues from growth stage programmes under both existing and new license and collaboration agreements, which may include non-refundable license fees. 

PureTech is now sitting on cash and equivalents of $247.5m, a drop of 12% on the $281.5m over the year. Chief operating officer Stephen Muniz said this leaves the group well-positioned to fund the upcoming clinical trials and ongoing pre-clinical development.

Bought the pharm

If you want a risky turnaround play, this is it. You are gambling on the company’s success in generating more revenue than it spends on R&D. Its valuation and earnings per share forecasts can give you no indication either. The pipeline looks rich, with PureTech well-positioned to deliver novel medicines and drive major value for shareholders. It remains a punt, but biopharma usually is.

With a far larger market cap of £2.24bn, FTSE 250 power generation specialist Aggreko (LSE: AGK) should be easier to assess. Its share price trades a whopping 65% lower than five years ago, as it has felt the heat from the oil and gas industry downturn and Latin American slowdown.

Heat is on

Earlier this month it posted a healthy 16% rise in first-half group revenue to £792m, excluding exceptional items, but this was disappointingly flat after excluding fuel and currency fluctuations. A 10% drop in profit before tax and exceptional items to £63m was a further blow, although an 84% leap in operating cash flow to £184m partly made up for that.

Chief executive Chris Weston reckons Aggreko is making good progress in boosting its product offering and reducing its cost base, with £100m of cash savings targeted. However, the turnaround has some way to go. Earnings per share are forecast to fall 8% in 2017 for what will be the fifth successive annual drop, but there is light at the end of the tunnel with City analysts suggesting a 12% rise in 2018.

Growth hope

Trading at 13.9 times earnings with a PEG of -1, there is value in this stock. The current yield of 3.3% will keep you warm while you wait for Aggreko to power on again.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

This FTSE 100 stock is down over 30% in 12 months! Is now a good time to buy?

Jabran Khan delves deeper into this FTSE 100 stock that has seen its share price drop substantially in the past…

Read more »

A person holding onto a fan of twenty pound notes
Investing Articles

I’d buy this crashed FTSE 100 share for its near-7% dividend yield!

These five FTSE 100 shares have crashed, losing 18% to 25% of their value in one month. But I'd buy…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

How I’d invest a Stocks and Shares ISA with a 10-year time frame

Our writer explains how he focusses his Stocks and Shares investment choices by using a long-term perspective.

Read more »

UK money in a Jar on a background
Investing Articles

3 reasons to consider the 7% Legal & General dividend yield

The Legal & General dividend yield of 7% is one reason our writer would consider buying the shares for his…

Read more »

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

Should I buy this FTSE 250 defensive stock?

Jabran Khan is looking for defensive stock options for his holdings and delves deeper into this FTSE 250 food manufacturing…

Read more »

pink toy piggy money box on yellow background
Investing Articles

5 ‘no-brainer’ FTSE 250 shares to buy today

I'm seeing a lot of attractive dividend shares in the FTSE 250 right now. This approach gives me some very…

Read more »

Windmills for electric power production.
Investing Articles

The SSE share price slumps by 11%! Should I buy today?

The SSE share price tumbled today after talks of a windfall tax on electricity generators. Our writer considers if it’s…

Read more »

British Pennies on a Pound Note
Investing Articles

3 penny shares I own instead of Woodbois

Our writer prefers these three penny shares over hot stock Woodbois -- which is why he has bought them.

Read more »